논문검색
Author Min Kyoung Kim, M.D.1, Sung-Bae Kim, M.D., Ph.D.1, Jin Hee Ahn, M.D., Ph.D.1, Soon Im Lee, R.N.1, Sei-Hyun Ahn, M.D., Ph.D.2, Byung Ho Son, M.D., Ph.D.2, Gyungyub Gong, M.D., Ph.D.3, Hak-Hee Kim, M.D., Ph.D.4, Jung-Shin Lee, M.D., Ph.D.1, Yoon-Koo Kang, M.D., Ph.D.1 and Woo Kun Kim, M.D.1
Place of duty 1Division of Oncology, Department of Medicine, Departments of 2Surgery, 3Pathology and 4Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Title Gemcitabine Single or Combination Chemotherapy in Post Anthracycline and Taxane Salvage Treatment of Metastatic Breast Cancer: Retrospective Analysis of 124 Patients
Publicationinfo Cancer Res Treat 2006 Dec; 038(04): 206-213.
Key_word Gemcitabine, Chemotherapy, Combination, Breast neoplasms
Full-Text
Abstract Purpose: To evaluate the efficacy of gemcitabine- based chemotherapy, particularly in patients with anthracycline- and taxane-pretreated 2nd-line or greater metastatic breast cancer, and to compare gemcitabine monotherapy (G) with two gemcitabine-based doublets, gemcitabine/ vinorelbine (GV) and gemcitabine/capecitabine (GX). Materials and Methods: Of 124 consecutive patients who progressed after anthracycline- and taxane-containing chemotherapy, 58 received G alone, 38 received GV, and 28 received GX; their outcomes were analyzed retrospectively. Results: The median number of prior metastatic chemotherapy regimens was 2 (range 0∼4). Visceral metastases were observed in 65 patients (51.4%). The overall response rate was 19.3% (21 partial responses). After a median follow-up period of 21.4 months, the overall survival was 7.6 months (95% CI: 5.5∼9.6 months) and the median time to progression was 3.1 months (95% CI: 2.0∼4.2 months). Compared with monotherapy (G), combination therapy with vinorelbine or capecitabine (GV/ GX) was associated with a significantly higher response rate (8.2% vs. 28.3%, p=0.008) and a significantly longer median time to progression (2.8 vs. 3.5 months; p=0.028), but overall survival did not differ between the groups (7.4 vs. 8.2 months, respectively; p=0.54). Most of the adverse treatment-related events were mild to moderate in intensity. The most common adverse event was hematologic toxicity. Multivariate analysis showed that poor performance status and a short disease-free interval were independent prognostic factors for impaired overall survival. Conclusions: The combination of gemcitabine with vinorelbine or capecitabine was an active and well-tolerated treatment option for taxane- and anthracycline-pretreated 2nd-line or greater metastatic breast cancer patients, and gemcitabine-based doublets were more beneficial than gemcitabine monotherapy in alleviating symptoms for these patients. (Cancer Res Treat. 2006;38:206-213)
출판정보 대한암학회지 2006 Dec; 038(04): 206-213.